Search Results
237 items found for "Addex Therapeutics"
- Addex Therapeutics CEO Tim Dyer: There is a $4-bil market opportunity in dyskinesia
January 2022 "Watch our CEO Tim Dyer on AlphaStreet. In his interview, Mr. Dyer provides an overview of our #allostericmodulator pipeline and the potential $4 billion market for our lead compound #dipraglurant in #PDLID (#Parkinsonsdisease levodopa-induced #dyskinesia)." Read more at the source #DrGPCR #GPCR #IndustryNews
- Addex Therapeutics Completes Patient Enrollment For Dipraglurant Blepharospasm Phase 2 Clinical ...
April 2022 Addex Therapeutics Completes Patient Enrollment For Dipraglurant Blepharospasm Phase 2 Clinical Study " Geneva, Switzerland, April 13, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage
- Addex Reports 2022 Half Year and Second Quarter Financial Results and Provides Corporate Update
August 2022 "Geneva, Switzerland, August 18, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage priorities, including pursuing additional collaborations across our portfolio,” said Tim Dyer , CEO of Addex
- Addex Raises $10 Million In Equity Financing
December 2021 "Geneva, Switzerland, December 17, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq Additionally, Addex has agreed to issue to Armistice Capital unregistered warrants to purchase up to
- Addex Therapeutics To Release Full-Year 2021 Financial Results And Host Conference Call On March 10
March 2022 " Geneva, Switzerland, March 7, 2022 – Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-stage
- Addex raises $4.2 million in equity financing
July 2022 " Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 22, 2022 – Addex Therapeutics Additionally, Addex has agreed to issue to Armistice Capital unregistered pre-funded warrants to purchase
- Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for...
August 2022 Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for Substance Use Disorders "Geneva, Switzerland, August 15, 2022 - Addex Therapeutics (SIX and Nasdaq: As part of the amended agreement, Indivior will provide Addex with CHF 850,000 (approx. The reserved indications, where Addex retains exclusive rights to develop its own independent GABAB PAM
- Addex's strategic partner The Janssen Pharmaceutical Companies of Johnson & Johnson, Inc. has...
November 2021 Addex's strategic partner The Janssen Pharmaceutical Companies of Johnson & Johnson, Inc completed Phase 1 studies in Japan with JNJ-40411813 (ADX71149) " Geneva, Switzerland, November 15, 2021 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric
- Addex Expands Pipeline With Selective M4 Positive Allosteric Modulator Program For The Treatment ...
April 2022 Addex Expands Pipeline With Selective M4 Positive Allosteric Modulator Program For The Treatment Screening Platform Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 6, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric
- Applying Allosteric Modulator Pharmacology to Treat Dyskinesia and Other Movement Disorders with ...
Applying Allosteric Modulator Pharmacology to Treat Dyskinesia and Other Movement Disorders with Tim Dyer Addex Therapeutics " Tim Dyer is the Co-Founder and CEO of Addex Therapeutics , which is focusing on the Addex did not invent allosteric modulation but is pioneering the screening technologies to find these
- 📰 GPCR Weekly News, May 8 to 14, 2023
Continuing Study Addex Therapeutics in the 23rd BioEquity Europe Conference Simon Bekker-Jensen and Q1 2023 Financial Results And Provides Corporate Update Structure Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights OMass Therapeutics presented at the 23rd BioEquity Conference British Patient Capital Invests £10m in next-generation drug development company OMass Therapeutics GPCR Events, Meetings, and Webinars ASPET 2023 - American Society for Pharmacology and Experimental Therapeutics
- 📰 GPCR Weekly News, April 17 to 23, 2023
GPCRs in Neuroscience G protein coupled receptors as targets for transformative neuropsychiatric therapeutics GPCRs in Oncology and Immunology CCR6 as a Potential Target for Therapeutic Antibodies for the Treatment structures Inversago Pharma will present at BBHIC 2023 Orion Biotechnology attended the Swiss Biotech Day Addex Therapeutics attended the Swiss Biotech Day Sosei Heptares presented novel Computational Chemistry and GPCR Events, Meetings, and Webinars ASPET 2023 - American Society for Pharmacology and Experimental Therapeutics
- 📰 GPCR Weekly News, May 1 to 7, 2023
Industry News Addex Therapeutics to Release Q1 2023 Financial Results and Host Conference Call on May 11, 2023 Neurocrine Biosciences Reports First Quarter 2023 Financial Results Find Therapeutics welcomes critical, we cannot think about one size fits all” Dr Pina Cardarelli, Chief Scientific Officer, GPCR Therapeutics GPCR Events, Meetings, and Webinars ASPET 2023 - American Society for Pharmacology and Experimental Therapeutics
- 📰 GPCR Weekly News, July 31 to August 6, 2023
GPCR Symposium on 'GPCRs as Therapeutic Modalities' is set for September 22nd. binding of Drosophila Smaug to the GPCR Smoothened and to the germline inducer Oskar Industry News Addex Additional Chf 2.7 Million From Indivior In Extended Substance Use Disorder Research Collaboration Addex Therapeutics To Release Half-Year 2023 Financial Results And Host Conference Call On August 10, 2023
- 📰 GPCR Weekly News, February 6 to 12, 2023
rare IPO, raising $161M 3-drug combo leads to 'unprecedented' response in pancreatic cancer models Addex Therapeutics Ltd Strategic Partner Completes Enrollment in ADX71149 Epilepsy Phase 2 Study Part 1 IPO Raises $161M for GPCR-Based Drug Developer Structure Therapeutics Crinetics Pharmaceuticals Announces
- 📰 GPCR Weekly News, April 15 to 21, 2024
GPCRs in Oncology and Immunology Deciphering a GPCR-lncRNA-miRNA Nexus: Identification of an Aberrant Therapeutic more Deorphanization of G Protein Coupled Receptors (GPCRs): a historical perspective Industry News Addex Therapeutics Reports Full Year 2023 Financial Results And Provides Corporate Update Aelis Farma announces at the 19th Biopharma Drug Discovery Nexus Salipro Biotech will participate in BioKorea2024 Domain Therapeutics
- Tectonic Therapeutic Strengthens Leadership Team
July 2022 "July 19, 2022 07:00 AM Eastern Daylight Time BOSTON-- Tectonic Therapeutic , Inc. a pre-clinical
- Biased Agonism at the GLP-1 Receptor: A Pathway to Improved Therapeutic Outcomes
adipose tissue size more effectively than exendin, suggesting that biased agonism can lead to distinct therapeutic In conclusion, biased agonism at the GLP-1R represents a promising strategy for optimizing therapeutic continues to grow, it is likely to play an increasingly important role in the design of next-generation therapeutics Christopoulos, Signalling bias in new drug discovery: detection, quantification and therapeutic impact Drucker, D.J., Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1.
- Ermium Therapeutics has constituted its SAB
February 2022 " Ermium Therapeutics Announces the Formation of a Scientific Advisory Board comprising
- Unlocking the Therapeutic Potential of Previously Undruggable GPCRs
A New Wave of GPCR Drug Discovery GPCRs are considered highly druggable, with GPCR-targeting therapeutics Within the last two years, three investments stand out: · Tectonic Therapeutics: received $80 USD Series A round to develop small molecule drugs against difficult-to-drug GPCRs. · Domain Therapeutics Developing Small Protein Therapeutics with a Novel Discovery Platform One way to overcome the challenges About Orion Biotechnology Orion’s mission is to unlock the therapeutic potential of previously undruggable
- 📰 GPCR Weekly News, April 8 to 14, 2024
Protein Industry News Monash University retains its N° 2 global ranking for Pharmacy and Pharmacology Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024
- Domain Therapeutics Raises $42m Series A Financing
its best-in-class and first-in-class immuno-oncology programs STRASBOURG, France & MONTREAL- Domain Therapeutics
- GPCR Therapeutics Expands Scientific Advisory Board
May 2022 "Seoul, South Korea, 28 April 2022 – GPCR therapeutics , Inc., a venture-backed clinical stage
- Therapeutic validation of an orphan G protein‐coupled receptor
Historically, ligands for GPCRs have been identified before their receptor counterparts. With the cloning revolution, several unidentified receptors have been found and were labelled as “orphan” for their endogenous ligands. Orphan GPCRs have been shown to play key roles in various physiological functions, such as sensory perception, reproduction, development, growth, metabolism, and are also linked to major diseases, such as neuroinflammatory, metabolic and autoimmune diseases. Therefore, matching a ligand to an orphan GPCRs, the process of de-orphanizing, is of great importance in order to better understanding human physiology as well as to dissect the molecular mechanism governing the involvement of these receptors in human pathology. GPR84 is an example of an orphan GPCR (Sharman et al., 2011), although it is widely accepted that medium‐chain fatty acids (MCFAs) can bind to and activate this receptor with modest potency. GPR84 is a Gi‐coupled class A GPCR mainly expressed in immune cells and microglia in the brain (Wojciechowicz & Ma'ayan, 2020). GPR84 has been shown to be an attractive target in pro‐inflammatory conditions (Gagnon et al., 2018; Suzuki et al., 2013; Vermeire et al., 2017; Wojciechowicz & Ma'ayan, 2020) and efforts have been made to discover GPR84 antagonists. In this study Marsango et al. address two key questions in GPR84 biology and pharmacology: 1. how GPR84 expression profile correlates with physiological and pathological conditions? and 2. which ligands can be used as tool compounds to study the function and biology of this receptor? Regarding the first question, GPR84 overexpression in immune cells in a range of pro‐inflammatory disorders renders it a promising target in inflammatory and fibrotic conditions, including neuroinflammation (Audoy‐Remus et al., 2015), with ongoing clinical trials in idiopathic pulmonary fibrosis (Labéguère et al., 2014). GPR84 has been additionally proposed to be a potential biomarker in different inflammatory diseases (Arijs et al., 2011; Planell et al., 2017). Some studies have also reported GPR84 involvement in pain, atherosclerosis, and even metabolic disorders (Nicol et al., 2015, Audoy‐Remus et al., 2015, Du Toit et al., 2018). Regarding the second question, there is still a lot to be done in respect to tool compounds to study the function of this receptor towards clinical validation, as well as radiopharmaceuticals, including potential PET ligands, and suitable antibodies. Recent work has shown distinct functional outcomes of agonist ligands (Pillaiyar et al., 2018) with biased properties which can help to better elucidate the molecular pharmacology of this receptor. In addition, several GPR84 ligands have been described as well as GPR84 knockout mice. Among these ligands are orthosteric agonists such as alkylpyrimidine‐4,6‐diol derivatives (Liu et al., 2016; Zhang et al., 2016) and embelin (2,5‐dihydroxy‐3‐undecyl‐1,4‐benzoquinone) which is a natural product derived from the plant Embelia ribes (Gaidarov et al., 2018) which agonizes GPR84 but, interestingly, blocks the chemokine receptor CXCR2 and the adenosine A3 receptor (Gaidarov et al., 2018). IM (3,3′‐methylenebis‐1H‐indole) has been identified as a positive allosteric modulator of GPR84, a metabolite produced in vivo from indole‐3‐carbinol, which is present at high levels in some vegetables including broccoli and kale (Wang, Schoene, Milner, & Kim, 2012, Köse et al., 2020). GPR84 antagonists include a series of dihydropyrimidinoisoquinolinones (Labéguère et al., 2014), which behave as non‐competitive antagonists of GPR84 (Labéguère et al., 2020). From these series of compounds, GLPG1205 progressed into clinical development for the potential treatment of ulcerative colitis although it did not demonstrate sufficient efficacy (Labéguère et al., 2020). Overall, GPR84 is a promising target to exploit and the investment in better tools to study its function in both disease and physiological settings will likely potentiate drug discovery campaigns against this orphan GPCR. Check the original article at here! #GPCR #DrGPCR#Ecosystem
- GRK2 in cardiovascular disease and its potential as a therapeutic target
Thus, identifying novel molecular targets for developing HF therapeutics remains a key research focus Additionally, GPCR dysregulation underlies multiple models of cardiac pathology, and most pharmacological therapeutics
- Ono Enters into Collaboration Agreement with Domain Therapeutics and Université de Montréal for ...
April 2022 Ono Enters into Collaboration Agreement with Domain Therapeutics and Université de Montréal Gyo Sagara ; “Ono”) today announced that it has newly signed a collaboration agreement with Domain Therapeutics
- Structure Therapeutics Extends Financing, Advances Diabetes and Obesity Clinical Program and...
August 2022 Structure Therapeutics Extends Financing, Advances Diabetes and Obesity Clinical Program and Changes Name from ShouTi " San Francisco and Shanghai – August 1, 2022 – Structure Therapeutics (Structure Therapeutics), formerly known as ShouTi Inc., today announced it closed an oversubscribed In addition, Structure Therapeutics has completed dosing in a single ascending dose (SAD) Phase 1 study
- Domain Therapeutics and Explicyte enter partnership agreement in immuno-oncology
March 2022 " Explicyte grants Domain Therapeutics exclusivity on data related to GPCR implicated in Strasbourg and Bordeaux, France, March 10, 2022 – Domain Therapeutics , a biopharmaceutical company specializing their expertise to identify GPCR targets and associated biomarkers to discover and develop breakthrough therapeutic